Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 690721, 10 pages
http://dx.doi.org/10.1155/2015/690721
Research Article

Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines

1Biochemistry, Biochemical Analysis & Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece
2Department of Anatomy/Histology/Embryology, Unit of Bone and Soft Tissue Studies, School of Medicine, University of Patras, 26500 Patras, Greece
3Hematology Division, Department of Internal Medicine, University Hospital of Patras, 26500 Patras, Greece
4School of Health Professions, Department of Medical Laboratories, Technological Educational Institute of Larissa, 41110 Larissa, Greece

Received 30 April 2015; Revised 10 July 2015; Accepted 14 July 2015

Academic Editor: Martin Götte

Copyright © 2015 Angeliki Korpetinou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. V. Iozzo and L. Schaefer, “Proteoglycan form and function: a comprehensive nomenclature of proteoglycans,” Matrix Biology, vol. 42, pp. 11–55, 2015. View at Publisher · View at Google Scholar
  2. A. D. Theocharis, S. S. Skandalis, T. Neill et al., “Insights into the key roles of proteoglycans in breast cancer biology and translational medicine,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1855, no. 2, pp. 276–300, 2015. View at Publisher · View at Google Scholar
  3. S. O. Kolset and G. Pejler, “Serglycin: a structural and functional chameleon with wide impact on immune cells,” Journal of Immunology, vol. 187, no. 10, pp. 4927–4933, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. O. Kolset and H. Tveit, “Serglycin—structure and biology,” Cellular and Molecular Life Sciences, vol. 65, no. 7-8, pp. 1073–1085, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Purushothaman and B. P. Toole, “Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization,” The Journal of Biological Chemistry, vol. 289, no. 9, pp. 5499–5509, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. B. P. Schick, “Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis,” Progress in Molecular Biology and Translational Science, vol. 93, pp. 235–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. D. Theocharis, C. Seidel, M. Borset et al., “Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro,” The Journal of Biological Chemistry, vol. 281, no. 46, pp. 35116–35128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. L. He, X. Zhou, C. Qu, Y. Tang, Q. Zhang, and J. Hong, “Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients,” Medical Oncology, vol. 30, no. 4, article 707, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Korpetinou, S. S. Skandalis, A. Moustakas et al., “Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells,” PloS ONE, vol. 8, no. 10, Article ID e78157, 2013. View at Google Scholar · View at Scopus
  10. X.-J. Li, C. K. Ong, Y. Cao et al., “Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis,” Cancer Research, vol. 71, no. 8, pp. 3162–3172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Skliris, V. T. Labropoulou, D. J. Papachristou, A. Aletras, N. K. Karamanos, and A. D. Theocharis, “Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases,” FEBS Journal, vol. 280, no. 10, pp. 2342–2352, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Skliris, K. E. Happonen, E. Terpos et al., “Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma,” European Journal of Immunology, vol. 41, no. 2, pp. 437–449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. Kenny, G. Y. Lee, C. A. Myers et al., “The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression,” Molecular Oncology, vol. 1, no. 1, pp. 84–96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. M. Neve, K. Chin, J. Fridlyand et al., “A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes,” Cancer Cell, vol. 10, no. 6, pp. 515–527, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Haley, E. Haughney, E. Ullman, J. Bean, J. D. Haley, and M. Y. Fink, “Altered transcriptional control networks with trans-differentiation of isogenic mutant-KRas NSCLC models,” Frontiers in Oncology, vol. 4, article 344, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Mase, T. Iijima, N. Nakamura et al., “Intrabronchial orthotopic propagation of human lung adenocarcinoma—characterizations of tumorigenicity, invasion and metastasis,” Lung Cancer, vol. 36, no. 3, pp. 271–276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Stachnik, T. Yuen, J. Iqbal et al., “Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 50, pp. 17995–18000, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Tessema, D. M. Klinge, C. M. Yingling, K. Do, L. Van Neste, and S. A. Belinsky, “Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis,” Oncogene, vol. 29, no. 37, pp. 5159–5170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Yang, L. Song, H. Wang et al., “Combination of quercetin and 2-methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth,” PLOS ONE, vol. 10, no. 5, Article ID e0128277, 2015. View at Publisher · View at Google Scholar
  20. E. Oikonomou, K. Kothonidis, E. Taoufik et al., “Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo,” British Journal of Cancer, vol. 97, pp. 73–84, 2007. View at Google Scholar
  21. E. Oikonomou, E. Makrodouli, M. Evagelidou, T. Joyce, L. Probert, and A. Pintzas, “BRAFV600E efficient transformation and induction of microsatellite instability versus KRASG12V induction of senescence markers in human colon cancer cells,” Neoplasia, vol. 11, no. 11, pp. 1116–1131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Castronuevo, M. A. Thornton, L. E. McCarthy, J. Klimas, and B. P. Schick, “DNase I hypersensitivity patterns of the serglycin proteoglycan gene in resting and phorbol 12-myristate 13-acetate-stimulated human erythroleukemia (HEL), CHRF 288-11, and HL-60 cells compared with neutrophils and human umbilical vein endothelial cells,” The Journal of Biological Chemistry, vol. 278, no. 49, pp. 48704–48712, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Korpetinou, S. S. Skandalis, V. T. Labropoulou et al., “Serglycin: at the crossroad of inflammation and malignancy,” Frontiers in Oncology, vol. 3, article 327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Iida, J. Dorchak, R. Clancy et al., “Role for chondroitin sulfate glycosaminoglycan in NEDD9-mediated breast cancer cell growth,” Experimental Cell Research, vol. 330, no. 2, pp. 358–370, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Zhang, M. Yang, D. Yang, G. Cavey, P. Davidson, and G. Gibson, “Molecular interactions of MMP-13 C-terminal domain with chondrocyte proteins,” Connective Tissue Research, vol. 51, no. 3, pp. 230–239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Malla, E. Berg, A. D. Theocharis, G. Svineng, L. Uhlin-Hansen, and J.-O. Winberg, “In vitro reconstitution of complexes between pro-matrix metalloproteinase-9 and the proteoglycans serglycin and versican,” FEBS Journal, vol. 280, no. 12, pp. 2870–2887, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J.-O. Winberg, S. O. Kolset, E. Berg, and L. Uhlin-Hansen, “Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans,” Journal of Molecular Biology, vol. 304, no. 4, pp. 669–680, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. J.-O. Winberg, E. Berg, S. O. Kolset, and L. Uhlin-Hansen, “Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans,” European Journal of Biochemistry, vol. 270, no. 19, pp. 3996–4007, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Verrecchio, M. W. Germann, B. P. Schick, B. Kung, T. Twardowski, and J. D. San Antonio, “Design of peptides with high affinities for heparin and endothelial cell proteoglycans,” Journal of Biological Chemistry, vol. 275, no. 11, pp. 7701–7707, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. S.-W. Tyan, C.-H. Hsu, K.-L. Peng et al., “Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change,” PLoS ONE, vol. 7, no. 4, Article ID e35128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. A. J. Meen, I. Øynebråten, T. M. Reine et al., “Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROα/CXCL1,” The Journal of Biological Chemistry, vol. 286, no. 4, pp. 2636–2647, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. T. M. Reine, T. T. Vuong, T. G. Jenssen, and S. O. Kolset, “Serglycin secretion is part of the inflammatory response in activated primary human endothelial cells in vitro,” Biochimica et Biophysica Acta—General Subjects, vol. 1840, no. 8, pp. 2498–2505, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Hamilton, V. Basic, S. Andersson, M. Abrink, and M. Ringvall, “Loss of serglycin promotes primary tumor growth and vessel functionality in the RIP1-Tag2 mouse model for spontaneous insulinoma formation,” PLoS ONE, vol. 10, no. 5, Article ID e0126688, 2015. View at Publisher · View at Google Scholar